Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom to Develop, Market Prenatal Blood Incompatibility Test with Lenitex

This article has been updated from a previous version, which mistakenly stated that the test will be based on Sequenom's RT-PCR technology instead of Sequenom's patent rights.  

NEW YORK (GenomeWeb News) - Sequenom and genetic screening company Lenetix have entered into a licensing and development collaboration to develop and market a prenatal Rhesus D incompatibility test, the companies said today.

The non-invasive test will be based on Sequenom’s patent rights and RT-PCR methodology, and is expected to be on the US market in the first half of 2007, the companies said.
 
RhD, a state of blood incompatibility between a pregnant woman and her fetus, can lead to death from anemia. The companies said RhD occurs in 10 percent of US pregnancies, or 400,000 cases per year.
 
Sequenom CEO Harry Stylii said the collaboration is an important development for the company as it continues its strategy in the non-invasive prenatal diagnostics market.
Financial terms of the agreement were not released.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.